

1 **Supplemental Information**

2 **Homocysteine promotes hepatic steatosis by activating the adipocyte** 3 **lipolysis in a HIF1 α -ERO1 α -dependent oxidative stress manner**

4
5 Yu Yan^a, Xun Wu^{b,c}, Pengcheng Wang^a, Songyang Zhang^a, Lulu Sun^a, Yang Zhao^d,
6 GuangYi Zeng^a, Bo Liu^a, Guoheng Xu^a, Huiying Liu^a, Lei Wang^{b,c*}, Xian Wang^{a*} and
7 Changtao Jiang^{a,e,f*}

8
9 ^aDepartment of Physiology and Pathophysiology, School of Basic Medical Sciences,
10 Peking University, Key Laboratory of Molecular Cardiovascular Science, Ministry of
11 Education, Beijing 100191, People's Republic of China

12 ^bNational Laboratory of Biomacromolecules, CAS Center for Excellence in
13 Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing
14 100101, People's Republic of China

15 ^cCollege of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049,
16 People's Republic of China

17 ^dDepartment of Laboratory Medicine, Peking University Third Hospital, Beijing
18 100191, People's Republic of China


19 ^eCenter of Basic Medical Research, Institute of Medical Innovation and Research,
20 Third Hospital, Peking University, Beijing, 100191, PR China

21 ^fCenter for Obesity and Metabolic Disease Research, School of Basic Medical
22 Sciences, Peking University, Beijing, 100191, PR China

23 *Correspondence to Changtao Jiang (Tel: +86-10-82801440, E-mail address:
24 jiangchangtao@bjmu.edu.cn), Xian Wang (Tel: +86-10-82801443, E-mail address:
25 xwang@bjmu.edu.cn) and Lei Wang (Tel: +86-10-64888501, E-mail address:
26 wanglei@ibp.ac.cn).

27

28 **Supplementary Figures**



29


30 **Figure S1. Hcy activates the lipolytic process in adipose tissue (Related to Figure**
 31 **1)**

32 (A-D) Levels of plasma Hcy, Met, SAM and SAH (n=6). Met, methionine; SAM, S-
 33 adenosylmethionine; SAH, S-adenosyl-L-homocysteine.

34 C57BL/6 mice (8 weeks old) were administered Hcy in the drinking water for 4 weeks.
35 (E) Protein levels of ATGL and phosphorylation levels of HSL at the Ser660 and
36 Ser563 residues (n=4). (F) The relative expression of genes involved in adipose tissue
37 lipolysis (n=6).

38 C57BL/6 mice (8 weeks old) were administered Hcy in the drinking water for 2 or 4
39 weeks. (G, H) Plasma FFAs and glycerol levels after fasting for 24 h at the indicated
40 time (n=6). (A) Mann-Whitney U test and (B-H) Two-tailed Student's t-test: * $P < 0.05$,
41 ** $P < 0.01$ compared to the vehicle group.


42 (I) Isolated mice eWAT were incubated with or without 500 μM Hcy for 8 h, the
43 glycerol release per hour in freshly changed medium was examined (n=6). ** $P < 0.01$
44 compared to the control group (J, K) After pretreatment with lipolysis inhibitor for 1 h,
45 the eWAT were treated with Hcy (500 μM) for 8h. The glycerol release per hour in
46 freshly changed medium was detected. Atglistatin, ATGL inhibitor, 10 μM ; BAY 59-
47 9435, HSL inhibitor, 5 μM . ** $P < 0.01$ compared to the Hcy group. All of the data are
48 presented as the means \pm SEM.



49

50 **Figure S2. Hcy upregulates the expression of ERO1α (Related to Figure 4)**

51 (A) The relative expression of genes related to ER stress markers in the vehicle or HHcy
 52 mice (n=6). (B) C57BL/6 mice (8 weeks old) were administered Hcy in the drinking
 53 water for 4 weeks. Protein levels of ERO1α (n=3). (C, D) 3T3-L1 cells transduced with
 54 lentiviral control shRNA (shCtrl) or shEro1a for more than 72 h were treated with 500
 55 μM Hcy. The protein and mRNA levels of ERO1α (n=3 or 5).
 56 All of the data are presented as the means ± SEM. (A, B) Two-tailed Student's t-test:
 57 ** $P < 0.01$ compared to the vehicle group. (C, D) One-way ANOVA with Tukey's
 58 post-hoc test: ** $P < 0.01$ compared to the control + shCtrl group. ## $P < 0.01$ compared
 59 to the Hcy + shCtrl group.



60


61 **Figure S3. Activation of HIF1 α mediates Hcy-induced ERO1 α expression in**
 62 **adipocytes (Related to Figure 5)**

63 (A, B) Protein and mRNA levels of HIF1 α in the eWAT of vehicle and HHcy mice
 64 (n=3 or 6). Two-tailed Student's t-test: ** $P < 0.01$ compared to the vehicle group. (C)

65 The relative expression of the *Hif1a* and *Pdk1* genes in the eWAT of *Hif1a*^{fl/fl} and
 66 *Hif1a* ^{Δ Adipo} mice after 8 weeks on an HMD (n=6). Two-tailed Student's t-test: ** $P <$

67 0.01 compared to the *Hif1a*^{fl/fl} + Hcy group. (D) The mRNA levels of HIF1 α in the
 68 eWAT of *Hif1a*^{+/+} and Ad*Hif1a*^{LSL/LSL} mice (n=6). Two-tailed Student's t-test: ** $P <$

69 0.01 compared to the *Hif1a*^{+/+} group. All of the data are presented as the means \pm SEM.



70

71 **Figure S4. The lipolytic gene was downregulated in Hcy-treated *Hif1a^{ΔAdipo}* mice**
 72 **(Related to Figure 6)**

73 (A-C) The relative expression of genes involved in TG synthesis, fatty acid oxidation
 74 and lipolysis (n=6). All of the data are presented as the means ± SEM. Two-tailed
 75 Student's t-test: ** $P < 0.01$ compared to the *Hif1a^{fl/fl}* + HHcy group.

76

77

78

79

80

81

82

83

84 **Supplementary Tables**85 **Table S1**86 **Characteristical data for nonhyperhomocysteinemia or hyperhomocysteinemia**

Groups	Nonhyperhomocysteinemia	Hyperhomocysteinemia
Sex, M/F, n/n	13/39	43/15
Age, yr	43.5±1.7	47.1±2.3
Body mass index, kg/m ²	21.80±0.22	22.45±0.26
Homocysteine, µmol/l	9.72±0.31	29.96±2.15**
Triglycerides, mmol/l	0.75±0.02	1.64±0.10**
Total cholesterol, mmol/l	4.45±0.12	4.52±0.11
HDL cholesterol, mmol/l	1.51±0.05	1.17±0.03**
LDL cholesterol, mmol/l	2.63±0.09	2.85±0.10

87 Data are expressed by mean ± SEM. ***P* < 0.01 compared to the nonhyperhomo-
88 cysteinemia group.

89

90 **Table S2. Primer sequences for qPCR**

qPCR primers	Sequence (5' to 3')
m <i>Dgat1</i> u	TCCGTCCAGGGTGGTAGTG
m <i>Dgat1</i> l	TGAACAAAGAATCTTGCAGACGA
m <i>Dgat2</i> u	GCGCTACTTCCGAGACTACTT
m <i>Dgat2</i> l	GGGCCTTATGCCAGGAAACT
m <i>Atgl</i> u	CTGAGAATCACCATTCCCACATC
m <i>Atgl</i> l	CACAGCATGTAAGGGGGAGA
m <i>Hsl</i> u	CCAGCCTGAGGGCTTACTG
m <i>Hsl</i> l	CTCCATTGACTGTGACATCTCG
m <i>Mgl</i> u	AGGCGAACTCCACAGAATGTT

m <i>Mgl</i> l	ACAAAAGAGGTA	CTGTCCGTCT
m <i>Perilipin</i> u	GGGACCTGTGAG	TGCTTCC
m <i>Perilipin</i> l	GTATTGAAGAGCC	GGGATCTTTT
m <i>CGI58</i> u	TGGTGTCCCACAT	CTACATCA
m <i>CGI58</i> l	CAGCGTCCATATT	CTGTTTCCA
m <i>Cd36</i> u	AGATGACGTGGCA	AAGAACAG
m <i>Cd36</i> l	CCTTGGCTAGATA	ACGAACTCTG
m <i>Fabp1</i> u	ATGAACTTCTCCG	GCAAGTACC
m <i>Fabp1</i> l	CTGACACCCCCTT	GATGTCC
m <i>Fasn</i> u	AAGTTGCCCGAGT	CAGAGAACC
m <i>Fasn</i> l	ATCCATAGAGCCC	CAGCCTTCCATC
m <i>Acc</i> u	GATGAACCATCTC	CGTTGGC
m <i>Acc</i> l	GACCCAATTATGA	ATCGGGAGTG
m <i>Srebplc</i> u	GGAGCCATGGATT	GACATT
m <i>Srebplc</i> l	GCTTCCAGAGAGG	AGGCCAG
m <i>Cpt1a</i> u	CTCCGCCTGAGCC	ATGAAG
m <i>Cpt1a</i> l	CACCAGTGATGAT	GCCATTCT
m <i>Ppara</i> u	AGAGCCCCATCTG	TCCTCTC
m <i>Ppara</i> l	ACTGGTAGTCTGCA	AAAACCAAA
m <i>Acox1</i> u	GGGCACGGCTATT	CTCACAG
m <i>Acox1</i> l	CATCAAGAACCTG	GCCGTCT
m <i>ApoB</i> u	AAGCACCTCCGAA	AGTACGTG
m <i>ApoB</i> l	CTCCAGCTCTACCT	TACAGTTGA
m <i>Mttp</i> u	CTCTTGGCAGTGCT	TTTTTCTCT
m <i>Mttp</i> l	GAGCTTGTATAGCC	GCTCATT
m <i>Erola</i> u	TTCTGCCAGGTTAG	TGGTTACC
m <i>Erola</i> l	GTTTGACGGCACAG	TCTCTTC
m <i>Hif1a</i> u	ATAGCTTCGCAGA	ATGCTCAGA

m <i>Hif1a l</i>	CAGTCACCTGGTTGCTGCAA
m <i>Atf6 u</i>	GACTCACCCATCCGAGTTGTG
m <i>Atf6 l</i>	CTCCCAGTCTTCATCTGGTCC
m <i>Atf4 u</i>	ATGGCGCTCTTCACGAAATC
m <i>Atf4 l</i>	ACTGGTCGAAGGGGTCATCAA
m <i>Chop u</i>	CTGGAAGCCTGGTATGAGGAT
m <i>Chop l</i>	CAGGGTCAAGAGTAGTGAAGGT
m <i>Bip u</i>	ACTTGGGGACCACCTATTCTT
m <i>Bip l</i>	ATCGCCAATCAGACGCTCC

91

92

Table S3. Primer sequences for ChIP

ChIP primers	Sequence (5' to 3')
<i>Erola</i> HRE1 u	GCCAGGTGTACCGGAGG
<i>Erola</i> HRE1 l	TGTCCACGCGAGCCT
<i>Erola</i> HRE2 u	TACCCCGACCCCGGAAG
<i>Erola</i> HRE2 l	CTCTGTCCACGCGAGCCT

93